BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 33541866)

  • 1. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
    Younes R; Govaere O; Petta S; Miele L; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; McLeod D; Pareja MJ; Fracanzani AL; Aller R; Rosso C; Ampuero J; Gallego-Durán R; Armandi A; Caviglia GP; Zaki MYW; Liguori A; Francione P; Pennisi G; Grieco A; Birolo G; Fariselli P; Eslam M; Valenti L; George J; Romero-Gómez M; Anstee QM; Bugianesi E
    Gut; 2022 Feb; 71(2):382-390. PubMed ID: 33541866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study.
    Semmler G; Wernly S; Bachmayer S; Wernly B; Schwenoha L; Huber-Schönauer U; Stickel F; Niederseer D; Aigner E; Datz C
    Clin Transl Gastroenterol; 2021 Apr; 12(4):e00326. PubMed ID: 33821832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis.
    Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
    Ann Hepatol; 2024; 29(3):101288. PubMed ID: 38278181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver.
    Feldman A; Eder SK; Felder TK; Kedenko L; Paulweber B; Stadlmayr A; Huber-Schönauer U; Niederseer D; Stickel F; Auer S; Haschke-Becher E; Patsch W; Datz C; Aigner E
    Am J Gastroenterol; 2017 Jan; 112(1):102-110. PubMed ID: 27527746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects.
    Feldman A; Wernly B; Strebinger G; Eder SK; Zandanell S; Niederseer D; Strasser M; Haufe H; Sotlar K; Paulweber B; Datz C; Aigner E
    J Gastrointestin Liver Dis; 2021 Sep; 30(3):366-373. PubMed ID: 34375373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients.
    Hirose S; Matsumoto K; Tatemichi M; Tsuruya K; Anzai K; Arase Y; Shiraishi K; Suzuki M; Ieda S; Kagawa T
    PLoS One; 2020; 15(11):e0241770. PubMed ID: 33186403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka.
    Niriella MA; Kasturiratne A; Pathmeswaran A; De Silva ST; Perera KR; Subasinghe SKCE; Kodisinghe SK; Piyaratna TACL; Vithiya K; Dassanayaka AS; De Silva AP; Wickramasinghe AR; Takeuchi F; Kato N; de Silva HJ
    Hepatol Int; 2019 May; 13(3):314-322. PubMed ID: 30539516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
    Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
    World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus.
    Chen N; Zhou J; Wang K; Li X; Li Z
    BMJ Open Diabetes Res Care; 2023 Feb; 11(1):. PubMed ID: 36792168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary inflammatory impact on NAFLD development in obese vs. lean individuals: an analysis based on NHANES 2003-2018.
    Li L; Shu X; Yi Y; Wang C; Li J; Ding Y; Li J; Chang Y
    Lipids Health Dis; 2024 Apr; 23(1):127. PubMed ID: 38685122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease.
    Arvind A; Henson JB; Osganian SA; Nath C; Steinhagen LM; Memel ZN; Donovan A; Balogun O; Chung RT; Simon TG; Corey KE
    Hepatol Commun; 2022 Feb; 6(2):309-319. PubMed ID: 34558862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.
    Li MR; Li JZ; Li JY; Wang CC; Yuan RK; Ye LH; Liu YY; Liang XJ; Zhang HC; Liu ZQ; Zeng DY; Zhang XD; Wang DH; Li JQ; Li TY; Yang L; Cao Y; Pan Y; Lin XG; Pan CQ; Dai EH; Dong ZY
    Obes Facts; 2023; 16(5):427-434. PubMed ID: 37231905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study.
    Ahmed OT; Gidener T; Mara KC; Larson JJ; Therneau TM; Allen AM
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1374-1381.e6. PubMed ID: 34265444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of body mass index on disease progression and outcomes in patients with nonalcoholic fatty liver disease.
    Biswas S; Vaishnav M; Farooqui N; Aggarwal A; Pathak P; Yadav R; Das P; Elhence A; Goel A; Mishra AK; Shalimar
    Postgrad Med J; 2023 Sep; 99(1176):1094-1103. PubMed ID: 37308443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.